Home
Search

Press Releases

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Featured Press Releases
BIO Statement on Most Favored Nation
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies:"For too many years, Americans have subsidized the research…
Learn more
BIO Statement on Industry Tariffs
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on the potential for 100% tariffs on branded or patented medicines in the US:“We share the Administration’s…
Learn more
BIO Extends Agreement with Avantor for Five…
Collaboration maximizes BIO members’ access to Avantor’s market-leading portfolio of products, materials, and services to accelerate scientific innovation. WASHINGTON, D.C., September 17, 2025 - The Biotechnology Innovation Organization (BIO)…
Learn more
All Press Releases
  • Show All
Search
Results
Event Tags
BIO and ICBA Release Updated Report on Biotechnology’s Role in Meeting UN Sustainable Development Goals
December 21, 2023
The Biotechnology Innovation Organization (BIO) released an updated report produced in partnership with the International Council of Biotechnology Associations (ICBA) that highlights biotechnology’s role in meeting the United Nations’ 17 Sustainable…
BIO Applauds U.N. FAO on Food and Climate Roadmap
December 14, 2023
The Biotechnology Innovation Organization (BIO) today welcomed the United Nations (U.N.) Food and Agriculture Organization’s announcement of a new roadmap outlining how the world can attain global food security by 2050 without breaching the global…
SCOTUS should preserve FDA's "mandated authority" and "scientific and medical expertise" in new case
December 13, 2023
Today, the Supreme Court announced it will soon weigh in on a case that challenges how the Food and Drug Administration (FDA) regulates mifepristone, a drug it approved almost 25 years ago. BIO interim president and CEO, Rachel King, made the…
New Survey Finds Majority of Americans Support Incentivizing Biotech to Address Climate Change
December 8, 2023
Most Americans Recognize that Biotech Is ‘Climate Tech’ A new poll from the Biotechnology Innovation Organization (BIO) shows that majorities of Americans agree that biotech plays an important role in addressing climate change and federal…
New BIO Poll Reveals Americans Strongly Support the Orphan Cures Act
December 7, 2023
Today, the Biotechnology Innovation Organization released a poll that shows voters overwhelmingly support the ORPHAN Cures Act, a recently introduced bill that would incentivize rare disease drug development.  The…
Using March-In as a Price Control Mechanism Is a “Dangerous Precedent To Set”
December 7, 2023
The White House just announced plans to use Bayh-Dole “march-in rights” to step in and license patent rights of drugs “developed with federal funding” to other manufacturers when the price of the drug is deemed too high. BIO's Chief Advocacy Officer…
Industry Leader and Globally Recognized Patient Advocate John F. Crowley Appointed to Lead BIO as President & CEO
December 5, 2023
The Biotechnology Innovation Organization (BIO) is proud to announce that industry leader and military veteran John F. Crowley will be its new President and CEO, effective March 4. He will replace Rachel King, a longtime BIO board member and…
BIO Commends USDA-APHIS Regulatory Announcements
November 21, 2023
The Department of Agriculture’s Animal and Plant Health Inspection Service recently announced exemptions from regulations under the Plant Protection Act for several categories of plants with genetic modification that could be achieved through…
BIO Statement on WHO Pandemic Accord Negotiating Draft
October 24, 2023
After the release of the World Health Organization Pandemic Accord negotiating draft, BIO's Senior Vice President of Infectious Disease & Emerging Science Policy, Phyllis Arthur, made the following remarks: “The Biotechnology Innovation…
New USITC report shows "no credible evidence" supporting a TRIPs waiver expansion
October 17, 2023
The United States International Trade Commission (USITC) today released its “COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities” report. The report aims to analyze various issues and information gaps concerning…
gooddaybio-cover-final
Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy. 

Sign Up Today